arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Wave Life Sciences Ltd.

WVE
$6.11 ▲ +0.09 (+1.50%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Wave Life Sciences Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.2B
Dividend Yield
Revenue Growth -73.9%
Op. Margin None
ROIC -16.3%
FCF / Share $-0.27
Trailing P/E
Price / Book 2.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.27M
↓ -73.9%
Net Income Profit after all expenses
$-26.09M
↑ +44.4%
Operating Margin Operating profit as % of sales
-81.8%
↑ +54.0%
FCF / Share Free cash flow per share
$-0.27
↑ +10.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
19
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters